Article

50 views
AstraZeneca’s leukemia drug, Moxetumomab pasudotox has received Priority Review designation from the US FDA for the treatment of adult patients ...
Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Access articles & resources worth up to $4000.

AstraZeneca’s leukemia drug, Moxetumomab pasudotox has received Priority Review designation from the US FDA for the treatment of adult patients ...

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Authentic, Ad-free Reporting
High-quality, Exclusive Content
Original Market Research Reports
Original Resources & Databases
Global Surveys & Guidelines
Lowest Subscription Pricing

Healthcare News You Won't Read Elsewhere

Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.

Access articles & resources worth up to $4000.

More in BRIEFING


BRIEFING

AstraZeneca Commits $90 Million in 5 Years to Improve Healthcare in India

Over the next five years, pharma giant, AstraZeneca will invest $90 million in India to improve the overall health outcomes in the country, by promoting innovation, skill development, and quality manufacturing.

BRIEFING

First-of-its-Kind FDA-Cleared Device Launched to Enhance Tear Production

Allergan has launched the first and the only FDA-cleared device TrueTear® to temporarily increase tear production in adult patients with inadequate tear production.

BRIEFING

Delhi-Based Healthcare Fintech Startup Raises $1 M in Seed Funding Round

Delhi-based healthcare financing startup, LetsMD has raised $1 million a pre-series A funding round led by SRI Capital.

Artificial Intelligence

First AI-Based Diabetic Retinopathy Detection Device Gets FDA Approval

The artificial intelligence (AI) based device called IDx-DR received US FDA approval for the screening of diabetic retinopathy- a common eye disease in diabetic patients that could lead to vision impairment and blindness.

Most Popular


GROW

7 New Ideas to Start a Healthcare Business in India (2018)

Highlights Herein, we are proposing the seven new healthcare business ideas in India in 2018 which are based on our ...

NEWLY PUBLISHED

Pharma Patents: Can India Reward Incremental Innovation?

Chandramouli Natarajan is an Associate Scientist, Ricon pharma LLC, Denville, USA. He has presented his opinion and views on the Pharmaceutical patents issues in India. This article is available for free to read and share.